Jurjen Versluis: Transplant for high-risk MDS | #18 | Trainee Pearls

Jurjen Versluis: Transplant for high-risk MDS | #18 | Trainee Pearls

Understanding MDS Mutations and Risk ScoresПодробнее

Understanding MDS Mutations and Risk Scores

Optimizing therapy for patients with high-risk MDSПодробнее

Optimizing therapy for patients with high-risk MDS

Should patients with TP53-mutated MDS receive stem cell transplant?Подробнее

Should patients with TP53-mutated MDS receive stem cell transplant?

Options available to patients with TP53-mutated MDS beyond stem cell transplantationПодробнее

Options available to patients with TP53-mutated MDS beyond stem cell transplantation

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic SyndromeПодробнее

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome

The curative potential of alloSCT in the treatment of HR-MDSПодробнее

The curative potential of alloSCT in the treatment of HR-MDS

The treatment protocol for higher risk MDSПодробнее

The treatment protocol for higher risk MDS

8th Seattle Patient Conference MDS Transplant OptionsПодробнее

8th Seattle Patient Conference MDS Transplant Options

MEG Rhein SystemПодробнее

MEG Rhein System

Genetic basis of MDSПодробнее

Genetic basis of MDS

The genetic landscape of MDS and impact on treatmentПодробнее

The genetic landscape of MDS and impact on treatment

MEDALIST: OS & risk of disease progression in patients with MDS treated with luspaterceptПодробнее

MEDALIST: OS & risk of disease progression in patients with MDS treated with luspatercept

The benefit of allogeneic transplantation in patients with TP53-mutated AMLПодробнее

The benefit of allogeneic transplantation in patients with TP53-mutated AML

Overall survival of patients following treatment with luspatercept in the MEDALIST trialПодробнее

Overall survival of patients following treatment with luspatercept in the MEDALIST trial

Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligibleПодробнее

Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligible

Molecular abnormalities influence patients with myelodysplastic syndromes after transplantПодробнее

Molecular abnormalities influence patients with myelodysplastic syndromes after transplant

Challenges in treating patients with TP53-mutated MCL & promising novel therapies being exploredПодробнее

Challenges in treating patients with TP53-mutated MCL & promising novel therapies being explored